TCT Conference In Brief

Clinical data news from the Transcatheter Cardiovascular Therapeutics conference held last week in Miami.

New data from St. Jude Medical Inc.’s FAME II trial evaluating the benefits of fractional flow reserve (FFR) as a guide to cardiac stenting show that the strategy is cost effective when compared to medical therapy alone, according to results presented last week at the annual Transcatheter Cardiovascular Therapeutics (TCT) symposium in Miami. Researchers found that at 12 months, the cost of FFR-guided up-front percutaneous coronary intervention (PCI) using St. Jude’s PressureWire Aeris or Certus FFR devices was $2,508 more expensive than medical therapy. But the FFR-guided strategy, in which patients found to have ischemia on the scan were randomized to stenting or medical therapy, was deemed cost effective due to the quality-of-life improvements observed with PCI. The overall cost-effectiveness of up-front PCI was $53,000 per quality-adjusted life year. The three-year projected cost for the FFR-guided PCI approach was $32,000 per quality-adjusted life year. “The cost gap narrows more than 50% by one year,” said lead investigator William Fearon, associate professor of medicine at Stanford University School of Medicine. “Since angina and quality of life are significantly improved by PCI, results of this study indicate that FFR-guided PCI appears to be economically attractive in an analysis of cost-effectiveness.”

FAME II’s full clinical results were first presented in August at the European Society of Cardiology Congress in Munich, showing that the rate of urgent revascularization was 86% lower for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Cardiosense Advances Noninvasive Heart Monitoring With Final Validation Study

 
• By 

Cardiosense has launched a nationwide clinical study, SEISMIC-HF II, to validate its non-invasive, AI-powered technology for monitoring heart failure. The data will be used to file for US regulatory clearance of the Cardiosense heart failure monitoring platform.

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

Salvia Bioelectronics Secures $60M In Series B To Advance Chronic Migraine Implant, Eyes US Trials

 
• By 

Medtech Insight spoke with Hubert Martens, CEO of Netherlands-based neuromodulation company Salvia Bioelectronics, about the company’s innovative implant for treating chronic migraines, ongoing clinical trials and plans for US clinical trials and commercialization.

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

More from R&D

Salvia Bioelectronics Secures $60M In Series B To Advance Chronic Migraine Implant, Eyes US Trials

 
• By 

Medtech Insight spoke with Hubert Martens, CEO of Netherlands-based neuromodulation company Salvia Bioelectronics, about the company’s innovative implant for treating chronic migraines, ongoing clinical trials and plans for US clinical trials and commercialization.

Bone Surgery Startup Surgify Medical Raises $7.9m

 

Surgify Medical’s selective drill tip, Surgify Halo, is “an obvious choice for surgeons,” said Boris Hofmann, head of ZEISS Ventures and lead investor in the company’s series A funding round.

German Bionic Launches ‘Strongest Exoskeleton To Date’

 

German Bionic’s new exoskeleton Exia helps healthcare practitioners, nurses, and other caregivers to lift and move patients by supporting muscle movement and reducing the risk of injury.